Mayinglong Pharmaceutical Group Co., Ltd. (SHA:600993)

SHA:600993 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	3,742	3,728	3,098	3,497	3,363	2,775
Other Revenue	-	-	38.3	35.12	22.53	16.54
Revenue	3,742	3,728	3,137	3,532	3,385	2,792
Revenue Growth (YoY)	14.82%	18.85%	-11.20%	4.35%	21.26%	3.19%
Cost of Revenue	1,994	1,992	1,829	2,038	2,019	1,688
Gross Profit	1,748	1,736	1,307	1,494	1,366	1,104
Selling, General & Admin	1,054	1,051	825.3	886.06	818.05	668.73
Research & Development	68.74	66.69	68.92	77.89	66.73	55.66
Other Operating Expenses	-2.1	-1.47	24.39	26.16	25.06	20.91
Operating Expenses	1,121	1,117	922.54	1,000	912.9	754.83
Operating Income	627.2	619.01	384.73	494.16	453.38	349.08
Interest Expense	-	-	-16.85	-11.69	-10.21	-6.98
Interest & Investment Income	13.66	13.66	151.5	98.92	78.85	30.4
Currency Exchange Gain (Loss)	-	-	0.05	0.04	-0.21	-0.06
Other Non Operating Income (Expenses)	33.63	41.23	-3.78	-6.22	-4.92	-5.08
EBT Excluding Unusual Items	674.5	673.9	515.65	575.22	516.89	367.36
Gain (Loss) on Sale of Investments	-1.15	-6.57	-0.35	-38.06	17.63	100.55
Gain (Loss) on Sale of Assets	0.02	0.02	1.12	-0.01	-0.5	7.58
Asset Writedown	-9.56	-9.8	-	-0.34	-0.44	-0.42
Other Unusual Items	-	-	8.28	22.33	14.58	22.62
Pretax Income	663.81	657.55	524.7	559.14	548.16	497.69
Income Tax Expense	108.73	109.26	72.86	79.78	74.11	67.05
Earnings From Continuing Operations	555.09	548.3	451.84	479.35	474.05	430.64
Minority Interest in Earnings	-21.09	-20.2	-8.59	-0.78	-9.46	-11.58
Net Income	534	528.09	443.25	478.57	464.59	419.06
Net Income to Common	534	528.09	443.25	478.57	464.59	419.06
Net Income Growth	17.80%	19.14%	-7.38%	3.01%	10.87%	16.42%
Shares Outstanding (Basic)	430	429	430	431	430	432
Shares Outstanding (Diluted)	430	429	430	431	430	432
Shares Change (YoY)	-0.23%	-0.23%	-0.19%	0.22%	-0.43%	0.81%
EPS (Basic)	1.24	1.23	1.03	1.11	1.08	0.97
EPS (Diluted)	1.24	1.23	1.03	1.11	1.08	0.97
EPS Growth	18.07%	19.42%	-7.21%	2.78%	11.34%	15.48%
Free Cash Flow	393.99	293.76	355.7	266.84	532.07	237.58
Free Cash Flow Per Share	0.92	0.68	0.83	0.62	1.24	0.55
Dividend Per Share	-	-	0.400	0.350	0.350	0.300
Dividend Growth	-	-	14.29%	-	16.67%	15.38%
Gross Margin	46.71%	46.55%	41.68%	42.30%	40.36%	39.54%
Operating Margin	16.76%	16.60%	12.26%	13.99%	13.39%	12.50%
Profit Margin	14.27%	14.17%	14.13%	13.55%	13.73%	15.01%
Free Cash Flow Margin	10.53%	7.88%	11.34%	7.55%	15.72%	8.51%
EBITDA	680.72	670.3	427.1	541.14	495.12	384.34
EBITDA Margin	18.19%	17.98%	13.62%	15.32%	14.63%	13.77%
D&A For EBITDA	53.52	51.29	42.37	46.98	41.74	35.25
EBIT	627.2	619.01	384.73	494.16	453.38	349.08
EBIT Margin	16.76%	16.60%	12.26%	13.99%	13.39%	12.50%
Effective Tax Rate	16.38%	16.61%	13.89%	14.27%	13.52%	13.47%
Revenue as Reported	-	-	3,137	3,532	3,385	2,792
Advertising Expenses	-	-	72.56	81.25	59.99	49.06

Source: S&P Global Market Intelligence. Standard template. Financial Sources.